Quarterly activity
Revenue: €177.4m, up 2.6% at CER1 and on a like-for-like basis2
Increase driven by EMEA (+4.5%), with an improvement in the situation in France, and by Asia (+6.0%); a decline in the Americas, impacted as anticipated by the situation at the Raleigh site
Operational deployment
Continued implementation of the remediation plan at the Raleigh site, in accordance with the action plan
Rollout of the Group's transformation plan in line with schedule, and the start of a procedure for informing and consulting the Economic and Social Committee a procedure for informing and consulting the Economic and Social Committee on a redundancy plan in France
2026 financial targets to be communicated by 23 July at the latest
Villepinte, 23 April 2026, 5.45 p.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is publishing its revenue for the first quarter of the year.
For the quarter ended 31 March 2026, the Group's sales increased by 2.6% at constant exchange rates (CER)1 and on a like-for-like basis2, and by 2.5% at CER. On a reported basis, first-quarter revenue amounted to €177.4 million, representing a slight decrease of 1.5% compared with the same period in 2025, including a negative foreign exchange impact of €7.2 million, mainly due to the depreciation of the US dollar and certain Asian currencies, particularly the Japanese yen and the Korean won. As announced, this development incorporates the negative impact of the situation at the Raleigh industrial site in North Carolina. It benefited from a favourable comparison base, as the first quarter of 2025 was marked by a contraction in activity in France following the reform of supply methods for contrast agents. The second quarter of 2026 will also compare against a demanding base, with the second quarter of 2025 marking one of the highest levels of activity in the Group's history.
Geographical breakdown of consolidated Group revenue (IFRS)
In millions of euros,at 31 March 2026
Q1 2025
Q1 2026
% change
% changeat CER
Sales in EMEA
80.3
84.1
+4.7%
+4.5%
Sales in the Americas
53.5
48.9
-8.7%
-3.0%
Sales in Asia
44.3
42.9
-3.4%
+6.0%
Total like-for-like
178.2
175.8
-1.3%
